Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 485Triple Negative Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms, Male 22Neoplasms 20Inflammatory Breast Neoplasms 20Neoplasm Metastasis 19Prostatic Neoplasms 17HER2-positive Breast Cancer 16Ovarian Neoplasms 13Lung Neoplasms 13Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 9Melanoma 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Neutropenia 6Breast Diseases 6Sarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Primary Breast Cancer 4Pathologic Complete Response 4Endometrial Neoplasms 4

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Docetaxel × Breast × Clear all
NCT04385563 2020-05-13

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
338 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡